Summary
Background Robust diagnostics, capable of detecting multiple variant of SARS-CoV-2 are necessary to mitigate the COVID-19 pandemic. In this study we directly compare the diagnostic capabilities of an LFI engineered with monoclonal antibodies (mAbs) originating from SARS-CoV-2 NP immunizations to the Abbott BinaxNOW™ COVID-19 Antigen CARD.
Methods Here we established a library of 18 mAbs specific to SARS-CoV-2 NP and used two of these mAbs (1CV7 and 1CV14) to generate a prototype antigen-detection lateral flow immunoassay (LFI). Samples consisting of remnant RT-PCR positive patient nasopharyngeal swabs preserved in viral transport media (VTM) were tested on the 1CV7/1CV14 LFI and the commercially available BinaxNOW™ test. Assays were allowed to resolve and results were recorded by two observers.
Findings A total of 98 remnant SARS-CoV-2 positive patient specimens were tested on both the 1CV7/1CV14 LFI and the BinaxNOW™ test. The 1CV7/1CV14 LFI detected 71 of the total 98 specimens, while the BinaxNOW™ test detected 52 of the 98 specimens. Additionally, the 1CV7/1CV14 LFI consistently detected samples with higher RT-PCR cycle threshold values than the BinaxNOW™ test.
Interpretation The 1CV7/1CV14 LFI outperformed the BinaxNOW™ test in the detection of BA.2, BA.2.12.1, and BA.5 Omicron sub-variants when testing remnant RT-PCR positive patient nasopharyngeal swabs diluted in viral transport media. BA.1 and BA.4 detection was comparable. The data suggest that mAbs derived from SARS-CoV-2 NP can aid in a more sensitive diagnostic immunoassay for COVID-19.
Funding The study was funded by the University of Nevada, Reno’s Research and Innovation Office, DxDiscovery, Inc. internal funds, and through AuCoin Laboratory internal funds.
Evidence before this study Since the onset of the pandemic, rapid antigen tests have proven themselves to be an accessible, accurate diagnostic platform. The widespread distribution of these tests has aided in curbing the COVID-19 pandemic. Data has shown that the tests manufactured at the beginning of the pandemic, utilizing monoclonal antibodies (mAbs) isolated from severe acute respiratory syndrome coronavirus (SARS-CoV), are less sensitive at detecting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron and Omicron subvariants. The reduced sensitivity can lead to diagnostic escape, and possible surges in COVID-19 caseloads
Added value of this study In this study, a total of 98 remnant RT-PCR confirmed SARS-CoV-2 positive clinical specimens were tested on both a prototype rapid antigen test in the form of a lateral flow immunoassay (LFI) (referred to as the 1CV7/1CV14 LFI) and the available Abbott BinaxNOW™ COVID-19 Antigen CARD. The 1CV7/1CV14 LFI detected markedly more specimens (71 of 98) specimens than the BinaxNOW™ test (52 of the 98).
Implications of all the available evidence This research suggests that that the use of mAbs isolated from immunizations with protein from SARS-CoV-2 may result in a diagnostic assay that is more sensitive in detection of SARS-CoV-2 Omicron subvariants, in comparison to the existing BinaxNOW™ COVID-19 Antigen CARD.
Competing Interest Statement
Amanda R. Burnham-Marusich and David P. AuCoin are shareholders of DxDiscovery, Inc. The remaining authors have no conflicts of interest to declare.
Funding Statement
This work was partially supported by funds from the University of Nevada, Reno Research and Innovation Office, DxDiscovery, Inc. internal funds, and through AuCoin Laboratory internal funds.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The University of Nevada, Reno Institutional Review Board (IRB) reviewed this project and determined this study to be EXEMPT FROM IRB REVIEW according to federal regulations and University policy. The Environmental and Biological Safety committee of the University of Nevada, Reno, approved the methods and techniques used in this study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data presented in this manuscript are available from the corresponding author upon reasonable request.
